BR112022016901A2 - Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso - Google Patents
Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de usoInfo
- Publication number
- BR112022016901A2 BR112022016901A2 BR112022016901A BR112022016901A BR112022016901A2 BR 112022016901 A2 BR112022016901 A2 BR 112022016901A2 BR 112022016901 A BR112022016901 A BR 112022016901A BR 112022016901 A BR112022016901 A BR 112022016901A BR 112022016901 A2 BR112022016901 A2 BR 112022016901A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- methods
- trk
- receptor
- degradating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
COMPOSTOS DE DEGRADAÇÃO DO RECEPTOR DE TROPOMIOSINA QUINASE (TRK) E MÉTODOS DE USO. Esta divulgação refere-se a compostos bivalentes (por exemplo, compostos de moléculas pequenas bifuncionais), composições compreendendo um ou mais dos compostos bivalentes e a métodos de uso dos compostos bivalentes para o tratamento de certas doenças em um sujeito em necessidade. A divulgação também se refere a métodos para identificar tais compostos bivalentes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020076748 | 2020-02-26 | ||
PCT/CN2021/078240 WO2021170109A1 (en) | 2020-02-26 | 2021-02-26 | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016901A2 true BR112022016901A2 (pt) | 2022-12-06 |
Family
ID=77490737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016901A BR112022016901A2 (pt) | 2020-02-26 | 2021-02-26 | Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230257380A1 (pt) |
EP (1) | EP4110772A4 (pt) |
JP (1) | JP2023514872A (pt) |
KR (1) | KR20230010070A (pt) |
CN (1) | CN115697989A (pt) |
AU (1) | AU2021225981A1 (pt) |
BR (1) | BR112022016901A2 (pt) |
CA (1) | CA3173262A1 (pt) |
IL (1) | IL295799A (pt) |
MX (1) | MX2022010465A (pt) |
WO (1) | WO2021170109A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020038415A1 (en) * | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
CN116648248A (zh) * | 2021-01-26 | 2023-08-25 | 成都茵创园医药科技有限公司 | 芳香化合物、含其的药物组合物及其应用 |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
CN115772180A (zh) * | 2021-09-08 | 2023-03-10 | 南京明德新药研发有限公司 | 戊二酰亚胺类化合物与其应用 |
WO2023055952A1 (en) * | 2021-09-29 | 2023-04-06 | C4 Therapeutics, Inc. | Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds |
CA3235512A1 (en) * | 2021-10-22 | 2023-04-27 | Xiaobao Yang | Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications |
EP4180428A1 (en) * | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
WO2023116835A1 (zh) * | 2021-12-24 | 2023-06-29 | 苏州开拓药业股份有限公司 | 一种具有酰亚胺骨架的多蛋白降解剂 |
TW202333670A (zh) * | 2022-01-04 | 2023-09-01 | 大陸商海思科醫藥集團股份有限公司 | 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用 |
WO2023193760A1 (en) * | 2022-04-06 | 2023-10-12 | Cullgen (Shanghai) , Inc. | Compounds and methods of treating cancers |
US20230416240A1 (en) * | 2022-06-16 | 2023-12-28 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
CN117510504A (zh) * | 2022-08-05 | 2024-02-06 | 深圳市新樾生物科技有限公司 | 蛋白激酶降解剂、药物及应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016013563A (es) * | 2014-04-14 | 2017-05-09 | Arvinas Inc | Moduladores de la proteolisis basados en imida y metodos de uso asociados. |
WO2016096709A1 (en) * | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
AU2016232705C1 (en) * | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
EP3455218A4 (en) * | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197051A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
EP3725771A4 (en) * | 2017-12-13 | 2021-10-13 | Shanghaitech University | ALK PROTEIN DEGRADATION AGENT AND ITS ANTITUMOR APPLICATION |
WO2020038415A1 (en) * | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
-
2021
- 2021-02-26 KR KR1020227033274A patent/KR20230010070A/ko unknown
- 2021-02-26 US US17/904,822 patent/US20230257380A1/en active Pending
- 2021-02-26 AU AU2021225981A patent/AU2021225981A1/en active Pending
- 2021-02-26 MX MX2022010465A patent/MX2022010465A/es unknown
- 2021-02-26 JP JP2022551553A patent/JP2023514872A/ja active Pending
- 2021-02-26 BR BR112022016901A patent/BR112022016901A2/pt unknown
- 2021-02-26 CN CN202180031506.7A patent/CN115697989A/zh active Pending
- 2021-02-26 WO PCT/CN2021/078240 patent/WO2021170109A1/en unknown
- 2021-02-26 EP EP21760113.7A patent/EP4110772A4/en active Pending
- 2021-02-26 CA CA3173262A patent/CA3173262A1/en active Pending
- 2021-02-26 IL IL295799A patent/IL295799A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230010070A (ko) | 2023-01-17 |
IL295799A (en) | 2022-10-01 |
AU2021225981A1 (en) | 2022-09-29 |
WO2021170109A1 (en) | 2021-09-02 |
US20230257380A1 (en) | 2023-08-17 |
JP2023514872A (ja) | 2023-04-11 |
CN115697989A (zh) | 2023-02-03 |
MX2022010465A (es) | 2022-12-13 |
CA3173262A1 (en) | 2021-09-02 |
EP4110772A1 (en) | 2023-01-04 |
EP4110772A4 (en) | 2024-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022016901A2 (pt) | Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso | |
MX2021001957A (es) | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). | |
DOP2023000041A (es) | Compuestos y métodos para el tratamiento de infecciones virales | |
BRPI0516751A (pt) | pirimidinas bicìclicas que inibem hcv | |
NI200900093A (es) | Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos. | |
BRPI0810064B8 (pt) | compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos | |
ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
CR11107A (es) | INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1 | |
BR112021023824A8 (pt) | Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica | |
BR112022007612A2 (pt) | Inibidores de raf quinases | |
BRPI0517921A (pt) | métodos para preparar compostos de indazol | |
CL2011000489A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala | |
BRPI0915592A2 (pt) | composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii | |
CY1107440T1 (el) | Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων | |
ECSP109957A (es) | Derivados de pirimidinil-piridazinona. | |
BRPI0612125A2 (pt) | compostos da fórmula (i), processo para a fabricação destes, composto da fórmula iiia, composições farmacêuticas, método para o tratamento e/ou profilaxia de doenças associadas à modulação dos receptores cb1 e uso de compostos | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
BR0313041A (pt) | Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos | |
BR112017026704A2 (pt) | uso | |
CL2009001936A1 (es) | Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006). | |
CL2011000195A1 (es) | Compuestos derivados de 5-alquinil-pirimidina, inhibidores de quinasas; composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer. | |
BRPI0912475B8 (pt) | compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica | |
BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
EA200601279A1 (ru) | Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина |